Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.

Hawkey CJ, Laine L, Simon T, Quan H, Shingo S, Evans J; Rofecoxib Rheumatoid Arthritis Endoscopy Study Group..

Gut. 2003 Jun;52(6):820-6. Erratum in: Gut. 2003 Dec;52(12):1800.

2.

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group..

N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528.

3.

Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.

Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, Geis GS.

Am J Gastroenterol. 2001 Apr;96(4):1019-27.

PMID:
11316141
4.

Rofecoxib for rheumatoid arthritis.

Garner SE, Fidan DD, Frankish RR, Judd MG, Towheed TE, Wells G, Tugwell P.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003685. Review.

PMID:
15674912
5.

Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.

Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, Dixon ME, Polis AB, Mollen AJ, Geba GP; ADVANTAGE Study Group..

Ann Intern Med. 2003 Oct 7;139(7):539-46.

PMID:
14530224
7.

Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials.

Hawkey CJ, Laine L, Harper SE, Quan HU, Bolognese JA, Mortensen E; Rofecoxib Osteoarthritis Endoscopy Multinational Study Group..

Aliment Pharmacol Ther. 2001 Oct;15(10):1593-601.

8.

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.

Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG; Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators..

Arch Intern Med. 2005 Jan 24;165(2):161-8. Erratum in: Arch Intern Med. 2005 Mar 14;165(5):551.

PMID:
15668361
9.

The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.

Watson DJ, Yu Q, Bolognese JA, Reicin AS, Simon TJ.

Curr Med Res Opin. 2004 Oct;20(10):1539-48.

PMID:
15462687
10.
11.

Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.

Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C.

Gastroenterology. 2003 Feb;124(2):288-92.

PMID:
12557133
12.

A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis.

Lohmander LS, McKeith D, Svensson O, Malmenäs M, Bolin L, Kalla A, Genti G, Szechinski J, Ramos-Remus C; STAR Multinational Study Group..

Ann Rheum Dis. 2005 Mar;64(3):449-56.

13.

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.

Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, Isakson PC, Verburg KM, Yu SS, Zhao WW, Geis GS.

JAMA. 1999 Nov 24;282(20):1921-8.

PMID:
10580457
14.

Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.

Hawkey CJ, Jackson L, Harper SE, Simon TJ, Mortensen E, Lines CR.

Aliment Pharmacol Ther. 2001 Jan;15(1):1-9. Review.

15.

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.

Laine L, Maller ES, Yu C, Quan H, Simon T.

Gastroenterology. 2004 Aug;127(2):395-402.

PMID:
15300570
16.

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.

Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ.

Circulation. 2001 Nov 6;104(19):2280-8.

17.
18.

Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis.

Sikes DH, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM.

Eur J Gastroenterol Hepatol. 2002 Oct;14(10):1101-11.

PMID:
12362101
19.

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.

Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B.

Am J Gastroenterol. 2003 Aug;98(8):1725-33.

PMID:
12907325
20.

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.

Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ.

JAMA. 1999 Nov 24;282(20):1929-33.

PMID:
10580458
Items per page

Supplemental Content

Support Center